Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct:79:16-28.
doi: 10.1016/j.cytogfr.2024.08.001. Epub 2024 Aug 10.

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Songyu Shen  1 , Yihan Hong  1 , Jiajun Huang  1 , Xiaosheng Qu  2 , Suren Rao Sooranna  3 , Sheng Lu  4 , Tian Li  5 , Bing Niu  6
Affiliations
Review

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Songyu Shen et al. Cytokine Growth Factor Rev. 2024 Oct.

Abstract

Tumor immunotherapy has garnered considerable attention, emerging as a new standard of care in cancer treatment. The conventional targets, such as VEGF and EGFR, have been extended to others including BRAF and PD-1/PD-L1, which have shown significant potential in recent cancer treatments. This review aims to succinctly overview the impact and mechanisms of therapies that modulate PD-1/PD-L1 expression by targeting VEGF, EGFR, LAG-3, CTLA-4 and BRAF. We investigated how modulation of PD-1/PD-L1 expression impacts growth factor signaling, shedding light on the interplay between immunomodulatory pathways and growth factor networks within the tumor microenvironment. By elucidating these interactions, we aim to provide insights into novel potential synergistic therapeutic strategies for cancer immunotherapy.

Keywords: BRAF; CTLA-4; EGFR; LAG-3; PD-1/PD-L1; Therapeutic targets; Tumor immunotherapy; VEGF.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declared that there is no conflict of interest.

Similar articles

See all similar articles

MeSH terms

LinkOut - more resources